129 related articles for article (PubMed ID: 32111758)
21. LRRC8A potentiates temozolomide sensitivity in glioma cells via activating mitochondria-dependent apoptotic pathway.
Yang C; He L; Chen G; Ning Z; Xia Z
Hum Cell; 2019 Jan; 32(1):41-50. PubMed ID: 30426452
[TBL] [Abstract][Full Text] [Related]
22. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol restores sensitivity of glioma cells to temozolamide through inhibiting the activation of Wnt signaling pathway.
Yang HC; Wang JY; Bu XY; Yang B; Wang BQ; Hu S; Yan ZY; Gao YS; Han SY; Qu MQ
J Cell Physiol; 2019 May; 234(5):6783-6800. PubMed ID: 30317578
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment but not subsequent coincubation with midazolam reduces the cytotoxicity of temozolomide in neuroblastoma cells.
Braun S; Bauer I; Pannen B; Werdehausen R
BMC Anesthesiol; 2015 Oct; 15():151. PubMed ID: 26475338
[TBL] [Abstract][Full Text] [Related]
25. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
26. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects.
Hattermann K; Held-Feindt J; Lucius R; Müerköster SS; Penfold ME; Schall TJ; Mentlein R
Cancer Res; 2010 Apr; 70(8):3299-308. PubMed ID: 20388803
[TBL] [Abstract][Full Text] [Related]
27. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
28. The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Chen PH; Shen WL; Shih CM; Ho KH; Cheng CH; Lin CW; Lee CC; Liu AJ; Chen KC
Neuropharmacology; 2017 Apr; 116():300-314. PubMed ID: 27986595
[TBL] [Abstract][Full Text] [Related]
29. Entry and exit of chemotherapeutically-promoted cellular dormancy in glioblastoma cells is differentially affected by the chemokines CXCL12, CXCL16, and CX3CL1.
Adamski V; Hattermann K; Kubelt C; Cohrs G; Lucius R; Synowitz M; Sebens S; Held-Feindt J
Oncogene; 2020 May; 39(22):4421-4435. PubMed ID: 32346064
[TBL] [Abstract][Full Text] [Related]
30. MiR-3116 sensitizes glioma cells to temozolomide by targeting FGFR1 and regulating the FGFR1/PI3K/AKT pathway.
Kong S; Cao Y; Li X; Li Z; Xin Y; Meng Y
J Cell Mol Med; 2020 Apr; 24(8):4677-4686. PubMed ID: 32181582
[TBL] [Abstract][Full Text] [Related]
31. LncRNA-XIST interacts with
Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y
Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025
[TBL] [Abstract][Full Text] [Related]
32. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
33. Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.
Wang J; Zhou F; Li Y; Li Q; Wu Z; Yu L; Yuan F; Liu J; Tian Y; Cao Y; Zhao Y; Zheng Y
Cell Cycle; 2017; 16(24):2355-2365. PubMed ID: 29108461
[TBL] [Abstract][Full Text] [Related]
34. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
35. Synergistic Anticancer Effects of Formononetin and Temozolomide on Glioma C6 Cells.
Zhang X; Ni Q; Wang Y; Fan H; Li Y
Biol Pharm Bull; 2018 Aug; 41(8):1194-1202. PubMed ID: 29848900
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Zhu D; Tu M; Zeng B; Cai L; Zheng W; Su Z; Yu Z
Cancer Med; 2017 Feb; 6(2):452-462. PubMed ID: 28064447
[TBL] [Abstract][Full Text] [Related]
37. Expression of chemokines and chemokine receptors in brain tumor tissue derived cells.
Razmkhah M; Arabpour F; Taghipour M; Mehrafshan A; Chenari N; Ghaderi A
Asian Pac J Cancer Prev; 2014; 15(17):7201-5. PubMed ID: 25227814
[TBL] [Abstract][Full Text] [Related]
38. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
39. Combined treatment with 2'-hydroxycinnamaldehyde and temozolomide suppresses glioblastoma tumorspheres by decreasing stemness and invasiveness.
Jeong H; Park J; Shim JK; Lee JE; Kim NH; Kim HS; Chang JH; Yook JI; Kang SG
J Neurooncol; 2019 May; 143(1):69-77. PubMed ID: 30887242
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma.
Xu JX; Yang Y; Zhang X; Luan XP
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1922-1931. PubMed ID: 32141561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]